Tele: 561.316.3330
Breaking Medical Device News

Sunday, October 17, 2021
HomeCLINICAL TRIALS, STUDIES, DATATIGER Trial Demonstrates High Safety and Efficacy for World’s First Adjustable Thrombectomy...

TIGER Trial Demonstrates High Safety and Efficacy for World’s First Adjustable Thrombectomy Device

March 24, 2021

TIGER TRIAL: The first adjustable, fully visible stent retriever shows superiority over conventional stent retrievers in a multicenter trial.

The late-breaking results were recently presented at the International Stroke Conference and published online in the journal Stroke.

TIGER trial, tigertriever
TIGERTRIEVER™ device

The TIGER Trial demonstrates a statistically significant 11-point improvement in the ability to restore blood flow to the brain during ischemic stroke and equivalent safety for the TIGERTRIEVER™ device compared to existing self-expanding stent retrievers.

“The trial confirmed that the TIGERTRIEVER is not only safe and effective but demonstrably improved outcomes over similar trials testing previous technology,” observed Jeffery Saver, MD, FAHA, Professor of Neurology and Director of the Comprehensive Stroke and Vascular Neurology Program at UCLA. “TIGERTRIEVER is an important advance in stroke treatment devices and a win for patients.”

Stent retriever devices (“stentrievers”) are the gold standard in treating large vessel ischemic strokes. Delivered minimally invasively through the vasculature, they expand into the clot to capture and remove the blockage as the device is retrieved. Prior to TIGERTRIEVER, the diameter and force of these devices were non-adjustable. With TIGERTRIEVER, physicians control the diameter and force as needed in response to real-time anatomical and procedural information. This ability to respond to situational feedback is known as intelligent control. The TIGER Trial concludes that these improvements provide meaningful benefit when removing the clot and treating stroke.

The TIGER Trial ended early after overwhelming effectiveness with 160 patients enrolled at 17 centers in the US and Israel. The trial demonstrates 84.6% revascularization success, compared to a 73.4% average from 6 recent pivotal stent retriever trials. This improvement translates to significantly better patient outcomes, with 58% of patients living independently after 90 days versus an average of 43% of patients from the previous device trials. Additionally, the TIGER Trial shows improved safety, with an 18.1% primary safety score versus a 20.4% historical average.

“TIGERTRIEVER’s intelligent control represents a new generation of stent retrievers as shown by the highest revascularization success rate of similar stent retriever trials,” said Walid Haddad, Chief Clinical Officer at Rapid Medical. “We applaud the work performed by our national principal investigators, Drs. Jeffery Saver of UCLA and Rishi Gupta of Wellstar Health System in Atlanta, GA, and all of our investigators and clinical site staff.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected

spot_img

Don't Miss

Ganymed Robotics Awarded a €2.5M Grant from the EC through the EIC Accelerator Program

Ganymed Robotics is developing a radically new approach to surgical robotics by combining computer vision, a branch of artificial intelligence, and mechatronics.

Global Healthcare Exchange Announces Acquisition of Explorer Surgical

Explorer Surgical will operate as a wholly-owned subsidiary of GHX.

Arlington Scientific Broadens Product Portfolio and Further Expands its Product Offering Through the acquisition of Non-Mammalian Blocking Buffers

Arlington Scientific, Inc. (ASI) is pleased to announce that it has acquired the non-mammalian blocking buffer product line from Clark McDermith, former owner of...

Laborie Medical Technologies Acquires Pelvalon

Laborie was represented by Piper Sandler (financial advisor) and Simpson Thacher & Bartlett LLP (legal advisor). Pelvalon was represented by J.P. Morgan Securities LLC (financial advisor) and Dorsey & Whitney LLP (legal advisor).

Herculite Products, Inc. Promotes Two Employees to New Roles

Paul Flaherty Chief Strategy Officer and Marco Angelone is being promoted to the role of Chief Financial Officer.

Prof. Joseph Kvedar Added to the Sweetch Advisory Board Member

Prof. Josdeph Kvedar is the current chair of the board at the American Telemedicine Association (ATA), formerly VP of Connected Health at Mass-Gen Brigham, co-chair of the American Medical Association (AMA) Digital Medicine Payment Advisory Group, and author of The Internet of Healthy Things and The New Mobile Age.

Sid Bala Named President of HealthChampion

Sid Bala is the former president and chief executive officer of alligatortek, a custom software applications company that was acquired by HealthChampion in 2020 where he led them for 27 years after he founded the business

Cochlear Announces FDA Approval and Clearance of first-of-its-kind Remote Care Capabilities for Nucleus and Baha Systems

The FDA approval for the cochlear implant solution and FDA clearance for the Baha solution is the first step in commercializing the product offering, anticipated spring 2022, and complement Cochlear's existing Remote Care offerings.

By using this website you agree to accept Medical Device News Magazine Privacy Policy